诺比素通过抑制PPARG/CD36通路的脂质吸收来缓解动脉样硬化
Heng Wang1, Qinqin Tian1, Ruijing Zhang2
1Department of Vascular Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Lipids in health and disease
|March 12, 2024
概括
诺比丁 (NOB) 通过抑制脂质吸收来缓解动脉样硬化. 这项研究确定了关键的基因和途径,证明了NOB.
科学领域:
- 生物化学和分子生物学
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 动脉样硬化 (AS) 是一种慢性炎症性疾病,由脂质积累和巨细胞透驱动.
- 诺比 (NOB) 显示出缓解AS的潜力,但其精确的机制需要阐明.
研究的目的:
- 阐明诺比 (NOB) 具有抗动脉样硬化作用的分子机制.
- 识别关键的基因,通路和细胞过程,涉及NOB对动脉样硬化的作用.
主要方法:
- 包括目标预测和途径丰富 (GO,KEGG) 在内的全面生物信息分析.
- 在体外测试 (细胞划痕,油红色O,ELISA,流细胞计,qRT-PCR,西部斑点) 和体内AS小鼠模型.
- 药物结合部位的预测 (DeepSite,AutoDock) 和免疫细胞透分析 (CIBERSORT).
主要成果:
- 在动脉样硬化的NOB干预中确定了141个潜在的点基因.
- 突出显示脂质代谢和动脉样硬化,以及流体剪切应激通路作为主导.
- 已确认的NOB在体外抑制脂质吸收和泡细胞形成,并在体内减轻AS病变,脂质积累和巨细胞透,与PPARG/CD36信号相关.
结论:
- 诺比 (NOB) 有效地减轻动脉样硬化.
- 该机制涉及通过氧酶增殖器激活受体玛 (PPARG) /CD36通路抑制脂质吸收.
- NOB证明了对动脉样硬化治疗的治疗潜力.
更多相关视频
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
447
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
447
01:29Cholesterol: Significance and Regulation
544
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
544